Drug stops spread of cancer in trial patients

Recipients of targeted gene treatment see their tumours shrink or stabilise

A new type of cancer treatment which kills malignant cells but leaves healthy cells unscathed has shown remarkable promise in its first trial.

More than half the 60 patients who received the targeted treatment saw their tumours shrink or stabilise, despite having previously tried other therapies which had failed to curb the progress of their disease. One patient who had advanced cancer is still in remission after two years.

The findings are announced today in the New England Journal of Medicine, which has taken the unusual decision to publish the small trial at such an early stage because of its "important results". An accompanying editorial says they "point to a new direction in the development of anti-cancer drugs".

The announcement comes five days after scientists at the Mayo Clinic in the US reported success with a new drug for prostate cancer. Two patients who had "inoperable" tumours were treated with the drug ipilimumab, a monoclonal antibody that stimulates the immune system. After one infusion, their tumours shrank enough to be surgically removed and both men have made a full recovery.

The latest development involves a different drug, olaparib, which works in a different way by targeting the genetic defect that causes cells to turn cancerous. In a process called "synthetic lethality", the drug has been engineered to chemically inhibit one type of gene, which then acts with the abnormal cancer gene to kill cancer cells in which both are present.

Initial tests have been carried out in patients with inherited breast, ovarian and prostate cancer caused by mutations in the BRCA1 and BRCA2 genes. People with these genetic mutations – about one in 500 people – have a high risk of developing cancer, of up to 80 per cent in the case of breast cancer.

Johann de Bono, a scientist at the Institute of Cancer Research and the leader of the study conducted in the UK and the Netherlands, said the trial showed "very impressive results".

"It's giving patients who have already tried many conventional treatments long periods of remission, free from the symptoms of cancer or major side effects." Professor Stan Kaye, the joint lead researcher from the institute, said: "This is a very important drug for the the treatment of BRCA1/2-related cancer. The next step is to test the drug on other more common types of ovarian and breast cancers where we hope it will be just as effective."

Julian Lewis, 62, who was diagnosed in 2004 with prostate cancer which had spread to his bones, has been on olaparib for two years. The drug has held his prostate cancer in check and the cancer in his bones "seems almost to have disappeared", he said.

Married with three daughters, he lives in Oxford and works as a cancer researcher himself. He is a BRCA2 mutation carrier and his sister died of ovarian cancer.

"It has always been the dream of cancer research to discover drugs that will kill the cancer cells while leaving healthy cells unharmed," he said.

"Now we have the tools in terms of genes to discover what has gone wrong in the cells of a cancer to make them misbehave. If you can pinpoint the key mutation that makes them dangerously different, you can use that to kill the cells selectively. In other words you can turn the weapon of the mischief-maker against the mischief-maker itself."

The drug is now being tested in further larger trials across the world.

Arts and Entertainment
Kirk Cameron is begging his Facebook fans to give him positive reviews
film
Sport
premier leagueMatch report: Arsenal 1 Man United 2
Arts and Entertainment
Jason goes on a special mission for the queen
tvReview: Everyone loves a CGI Cyclops and the BBC's Saturday night charmer is getting epic
Sport
Jonny May scores for England
rugby unionEngland 28 Samoa 9: Wing scores twice to help England record their first win in six
PROMOTED VIDEO
Life and Style
ebookNow available in paperback
Life and Style
ebooksA superb mix of recipes serving up the freshest of local produce in a delicious range of styles
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Reach Volunteering: Financial Trustee and Company Secretary

    Voluntary Only - Expenses Reimbursed: Reach Volunteering: A trustee (company d...

    Recruitment Genius: Senior Project Manager

    £45000 - £65000 per annum: Recruitment Genius: This is a fantastic opportunity...

    Recruitment Genius: Shopfitter

    Negotiable: Recruitment Genius: This is an opportunity to join a successful an...

    Recruitment Genius: Digital Sales Account Manager

    £25000 - £30000 per annum: Recruitment Genius: A Digital Sales Account Manager...

    Day In a Page

    Mau Mau uprising: Kenyans still waiting for justice join class action over Britain's role in the emergency

    Kenyans still waiting for justice over Mau Mau uprising

    Thousands join class action over Britain's role in the emergency
    Isis in Iraq: The trauma of the last six months has overwhelmed the remaining Christians in the country

    The last Christians in Iraq

    After 2,000 years, a community will try anything – including pretending to convert to Islam – to avoid losing everything, says Patrick Cockburn
    Black Friday: Helpful discounts for Christmas shoppers, or cynical marketing by desperate retailers?

    Helpful discounts for Christmas shoppers, or cynical marketing by desperate retailers?

    Britain braced for Black Friday
    Bill Cosby's persona goes from America's dad to date-rape drugs

    From America's dad to date-rape drugs

    Stories of Bill Cosby's alleged sexual assaults may have circulated widely in Hollywood, but they came as a shock to fans, says Rupert Cornwell
    Clare Balding: 'Women's sport is kicking off at last'

    Clare Balding: 'Women's sport is kicking off at last'

    As fans flock to see England women's Wembley debut against Germany, the TV presenter on an exciting 'sea change'
    Oh come, all ye multi-faithful: The Christmas jumper is in fashion, but should you wear your religion on your sleeve?

    Oh come, all ye multi-faithful

    The Christmas jumper is in fashion, but should you wear your religion on your sleeve?
    Dr Charles Heatley: The GP off to do battle in the war against Ebola

    The GP off to do battle in the war against Ebola

    Dr Charles Heatley on joining the NHS volunteers' team bound for Sierra Leone
    Flogging vlogging: First video bloggers conquered YouTube. Now they want us to buy their books

    Flogging vlogging

    First video bloggers conquered YouTube. Now they want us to buy their books
    Saturday Night Live vs The Daily Show: US channels wage comedy star wars

    Saturday Night Live vs The Daily Show

    US channels wage comedy star wars
    When is a wine made in Piedmont not a Piemonte wine? When EU rules make Italian vineyards invisible

    When is a wine made in Piedmont not a Piemonte wine?

    When EU rules make Italian vineyards invisible
    Look what's mushrooming now! Meat-free recipes and food scandals help one growing sector

    Look what's mushrooming now!

    Meat-free recipes and food scandals help one growing sector
    Neil Findlay is more a pink shrimp than a red firebrand

    More a pink shrimp than a red firebrand

    The vilification of the potential Scottish Labour leader Neil Findlay shows how one-note politics is today, say DJ Taylor
    Bill Granger recipes: Tenderstem broccoli omelette; Fried eggs with Mexican-style tomato and chilli sauce; Pan-fried cavolo nero with soft-boiled egg

    Oeuf quake

    Bill Granger's cracking egg recipes
    Terry Venables: Wayne Rooney is roaring again and the world knows that England are back

    Terry Venables column

    Wayne Rooney is roaring again and the world knows that England are back
    Michael Calvin: Abject leadership is allowing football’s age-old sores to fester

    Abject leadership is allowing football’s age-old sores to fester

    Those at the top are allowing the same issues to go unchallenged, says Michael Calvin